Latest news
Should FDA Approval of ORZEYFUL for Narcolepsy Type 1 Prompt Action From Takeda Pharmaceutical (TSE:4502) Investors? - simplywall.stsimplywall.st · Sat, 08 Aug 2026 11:46:03 GMTFDA approves Orzeyful, first drug to treat all symptoms of narcolepsy type 1 - managedhealthcareexecutive.commanagedhealthcareexecutive.com · Fri, 07 Aug 2026 20:06:51 GMTTakeda nets first-in-class advantage on narcolepsy drug’s FDA go-ahead - Pharmaceutical TechnologyPharmaceutical Technology · Fri, 07 Aug 2026 09:53:37 GMTFDA Approves Oveporexton, First Orexin Receptor Agonist for Narcolepsy Type 1 - Patient Care OnlinePatient Care Online · Fri, 07 Aug 2026 06:16:23 GMTFDA Approves Oveporexton for Adults With Narcolepsy Type 1 - HMP Global Learning NetworkHMP Global Learning Network · Thu, 06 Aug 2026 20:00:56 GMTTakeda approval ushers in new wave of sleep drugs - BioPharma DiveBioPharma Dive · Thu, 06 Aug 2026 16:10:45 GMTTakeda wins U.S. FDA approval for narcolepsy drug ORZEYFUL - International Business TimesInternational Business Times · Thu, 06 Aug 2026 15:36:29 GMTTakeda Achieves Major Milestone With Holistic Narcolepsy Drug Approval - BenzingaBenzinga · Thu, 06 Aug 2026 15:16:02 GMT